NCT05176951 is a Phase 2 clinical trial of Treprostinil Palmitil in Pulmonary Hypertension, sponsored by Insmed Incorporated.

Who is sponsoring NCT05176951?

NCT05176951 is sponsored by Insmed Incorporated.

What drugs are being tested in NCT05176951?

Interventions in NCT05176951: Treprostinil Palmitil, Placebo.

What condition does NCT05176951 study?

NCT05176951 studies Pulmonary Hypertension.

Is NCT05176951 still recruiting?

NCT05176951 is currently completed. Last updated 17 March 2025.

Last reviewed 2025-03-17 · How we verify

NCT05176951

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Completed Phase 2 Last updated 17 March 2025

What this trial tests

Phase 2 trial testing Treprostinil Palmitil in Pulmonary Hypertension in 39 participants. Completed in 14 March 2024.

Timeline

22 December 2022

Primary endpoint
14 March 2024

14 March 2024

Quick facts

Lead sponsor	Insmed Incorporated
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	39
Start date	22 December 2022
Primary completion	14 March 2024
Estimated completion	14 March 2024
Sites	25 locations across Italy, Belgium, United Kingdom, Germany, Argentina, Australia, Spain

Drugs / interventions tested

Treprostinil Palmitil — full drug profile →
Placebo

Conditions studied

Pulmonary Hypertension — all drugs for Pulmonary Hypertension →

Sponsor

Insmed Incorporated — full company profile →

Who can join

Adults 18 to 80, any sex, with Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to evaluate the safety and tolerability of treprostinil palmitil inhalation powder (TPIP) compared with placebo

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Pulmonary hypertension associated with lung diseases.
Shlobin OA, Adir Y, Barbera JA, Cottin V, et al · · 2024 · cited 53× · PMID 39209469 · DOI 10.1183/13993003.01200-2024
Review of the Diagnosis and Management of Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).
Kattih Z, Kim HC, Aryal S, Nathan SD. · · 2025 · cited 2× · PMID 40142837 · DOI 10.3390/jcm14062029
Abstract
· 2025

Verify or expand the search:

Other trials of Treprostinil Palmitil

Trials testing the same drug.

NCT05649748 — An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) · Phase 2, PHASE3 · active not recruiting
NCT05147805 — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants · Phase 2 · completed
NCT04791514 — A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH) · Phase 2 · terminated
NCT06939647 — An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arteri · available

Other recruiting trials for Pulmonary Hypertension

Currently open trials in the same condition.

NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
NCT07073820 — A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have P · Phase 2 · recruiting
NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
NCT07187206 — Safety and Efficacy of FETO in CDH Phase III · Phase 3 · recruiting
NCT07206173 — Londrina Activities of Daily Living Protocol in Pulmonary Hypertension · recruiting

Other Insmed Incorporated trials

Trials by the same sponsor.

NCT07481981 — A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants · Phase 3 · not yet recruiting
NCT07234032 — An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertens · Phase 3 · not yet recruiting
NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
NCT07102316 — A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalat · Phase 1 · completed
NCT06685835 — A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05176951 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Insmed Incorporated
Last refreshed: 17 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05176951.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing